Better tolerability. More convenient dosing. Less serious side effects. Fewer potential drug-drug interactions. These are some of the most common reasons why individuals living with HIV want or need to change their currently successful ART regimens.
But what do clinicians need to consider when determining which ART to switch to? What role do the patient’s comorbidities play in the selection process? How do changes in the patient’s condition not related to HIV affect the safety and efficacy of their current regimen? What does the evidence say?
Join us in this eHIV Review podcast for a case-based discussion with Dr. Natasha Chida, from the Division of Infectious Diseases at the Johns Hopkins University School of Medicine, about these increasingly important issues.
Assistant Professor of Medicine, Division of Infectious Diseases
Johns Hopkins University School of Medicine
Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California
Nurse Educator – Office Based Addiction Treatment, Training and Technical Assistance Program
Boston Medical Center
0.5 hour Physicians
0.5 contact hour Nurses
Launch date: July 22, 2021
Expiration date: July 21, 2023